Video

Dr Michael Cohen Discusses Accessibility of Future Gene Therapies

Michael N. Cohen, MD, FAAO, retinal surgeon at Wills Eye Hospital in Philadephia and Mid Atlantic Retina, speaks about the future of gene therapy and the accessibility and availability of these therapies moving forward.

Michael N. Cohen, MD, FAAO, retinal surgeon at Wills Eye Hospital in Philadephia and Mid Atlantic Retina, speaks about the future of gene therapy and the accessibility and availability of these therapies moving forward.

Transcript

What needs to be done to ensure that new gene therapies for retinal diseases are accessible and affordable for all patients?

So I think that's a great question, and the complexities of that answer are pretty deep. Ultimately, I think we have to make sure first that we have an effective medicine. Right now, it's really promising, and these phase 1 results up to 24 months in our safety and tolerability study look very good. And we look forward to a forthcoming phase 2 efficacy trial, looking at our medicine as a treatment for GA [geographic atrophy] in a patient with AMD [age-related macular degeneration].

More broadly, I think it's important to consider not just the impact that these medications with gene therapy have on the patients and in our case, their visual functioning, but also the potential elimination of some of the other burdens of the other treatments that could potentially be available. I think those are all important things to consider.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Merrill H. Stewart, MD
Nicolas Ferreyros, managing director, Community Oncology Alliance
Dr Ibrahim Aldoss
Jody Agena, PharmD, MBA, director of pharamcy operations, Virginia Cancer Specialists
Rachel Rohaidy, MD
Mansi Shah, MD
Miriam Freimer, MD
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Dr Pankit Vachhani
Dr Ibrahim Aldoss
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo